Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways

Cancer Research

Volumn 66, Issue 1, 2006, Pages 315-323

  Han, ShouWei ^a,b   Khuri, Fadlo R ^b   Roman, Jesse ^a,c  

^a Division of Pulmonary   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; FIBRONECTIN BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE LKB1; S6 KINASE; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; VERY LATE ACTIVATION ANTIGEN 5;

ARTICLE; CANCER SURVIVAL; CARCINOMA CELL; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CHROMOSOME 10; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS REGULATION; RECEPTOR UPREGULATION; TUMOR GROWTH;

CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FIBRONECTINS; HUMANS; INTEGRIN ALPHA5BETA1; LUNG NEOPLASMS; MULTIENZYME COMPLEXES; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RIBOSOMAL PROTEIN S6 KINASES; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 31544464931     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2367     Document Type: Article

References (45)

1. Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu H. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and Fnare up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res 2003;9:68-75.
2. Hegele A, Heidenreich A, Kropf J, et al. Plasma levels of cellular fibronectin in patients with localized and metastatic renal cell carcinoma. Tumour Biol 2004;25:111-6.
3. Hu M, Carles-Kinch KL, Zelinski DP, Kinch MS. EphA2 induction of fibronectin creates a permissive microenvironment for malignant cells. Mol Cancer Res 2004;2: 533-40.
4. Han JY, Kim HS, Lee SH, Park WS, Lee JY, Yoo NJ. Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: correlation with lymph node metastasis. Lung Cancer 2003;41:65-70.
5. Jakowlew SB, Mariano JM, You L, Mathias A. Differential regulation of protease and extracellular matrix protein expression by transforming growth factor-β 1 in non-small cell lung carcinoma cells and normal human bronchial epithelial cells. Biochim Biophys Acta 1997;1353:157-70.
6. Rintoul RC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung carcinoma. Clin Sci (Lond) 2002;102:417-24.
7. Han S, Sidell N, Susan Roser-Pager S. Roman J. Fibronectin stimulates human lung cancer cell growth by inducing cyclooxygenase-2 (COX-2) gene expression. Int J Cancer 2004;111:322-31.
8. Han S, Sidell N, Roman J. Fibronectin stimulates human lung carcinoma cell proliferation by suppressing p21 gene expression via signals involving Erk and Rho kinase. Cancer Lett 2005;219:71-81.
9. 1-S phase cell cycle progression in hepatocytes. Exp Cell Res 2004;300: 259-71.
10. Kijima T, Maulik G, Ma PC, Madhiwala P, Schaefer E, Salgia R. Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer. J Cell Mol Med 2003;7:157-64.
11. Tee AR, Blenis J. mTOR, translational control and human disease. Semin Cell Dev Biol 2005;16:29-37.
12. Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 2004;16: 564-75.
13. Rao RD, Buckner JC, Sarkaria JN. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer Drug Targets 2004;4:621-35.
14. Carraway H, Hidalgo M. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 2004;6:219-24.
15. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004;23:3151-71.
16. Kim HW, Park IK, Cho CS, et al. Aerosol delivery of glucosylated polyethylenimine/phosphatase and tensin homologue deleted on chromosome 10 complex suppresses Akt downstream pathways in the lung of K-ras null mice. Cancer Res 2004;64:7971-6.
17. Man SW, Lei ZM, Rao CV. Up-regulation of cyclooxygenase-2 gene expression by chorionic gonadotropin during the differentiation of human endometrial stromal cells into decidua. Endocrinology 1996;137: 1791-97.
18. Miyashita T, Kawakami A, Tamai M, et al. Akt is an endogenous inhibitor toward tumor necrosis factor-related apoptosis inducing ligand-mediated apoptosis in rheumatoid synovial cells. Biochem Biophys Res Commun 2003;312:397-04.
19. 1-integrin and phosphatidylinositol 3′-kinase/AKT signaling. Cancer Res 2003;63:5850-8.
20. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004;6:91-9.
21. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004;91:1420-4.
22. Zamecnik J, Vargova L, Homola A, Kodet R, Sykova E. Extracellular matrix glycoproteins and diffusion barriers in human astrocytic tumours. Neuropathol Appl Neurobiol 2004;30:338-50.
23. Carretero J, Medina PP, Pio R, Montuenga LM, Sanchez-Cespedes M. Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene 2004;23:4037-40.
24. Qiu Q, Yang M, Tsang BK, Gruslin A. Both mitogen-activated protein kinase and phosphatidylinositol 3-kinase signalling are required in epidermal growth factor-induced human trophoblast migration. Mol Hum Reprod 2004;10:677-84.
25. Kristof AS, Marks-Konczalik J, Billings E, Moss J. Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-γ is regulated by mammalian target of rapamycin. J Biol Chem 2003;278: 33637-44.
26. Gagnon V, Mathieu I, Sexton E, Leblanc K, Asselin E. AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 2004;94:785-95.
27. 1. J Cell Physiol 2005;202: 205-14.
28. 1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res 2004;64:4514-22.
29. Sakakibara K, Liu B, Hollenbeck ST, Kent KC. Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin (mTOR). Am J Physiol Heart Circ Physiol 2005;288:H2861-8.
30. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-37.
31. Neshat MS, Mellinghoff IK, Tran C, et al Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98:10314-19.
32. Luo Z, Saha AK, Xiang X, Ruderman NB. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005;26:69-76.
33. Ouchi N, Kobayashi H, Kihara S, et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 2004;279:1304-9.
34. Sullivan JE, Brocklehurst KJ, Marley AE, Carey F, Carling D, Beri RK. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett 1994;353:33-6.
35. Turcotte LP, Raney MA, Todd MK. ERK1/2 inhibition prevents contraction-induced increase in plasma membrane FAT/CD36 content and FA uptake in rodent muscle. Acta Physiol Scand 2005;184:131-9.
36. Dokladda K, Green KA, Pan DA, Hardie DG. PD98059 and U0126 activate AMP-activated protein kinase by increasing the cellular AMP:ATP ratio and not via inhibition of the MAP kinase pathway. FEBS Lett 2005; 579:236-40.
37. Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 2003;2:S169-77.
38. Savinska LO, Lyzogubov W, Usenko VS, et al. Immunohistochemical analysis of S6K1 and S6K2 expression in human breast tumors. Eksp Onkol 2004; 26:24-30.
39. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004;10: 8421-5.
40. Surace EI, Lusis E, Haipek CA, Gutmann DH. Functional significance of S6K overexpression in meningioma progression. Ann Neurol 2004;56:295-8.
41. Avdulov S, Li S, Michalek V, et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 2004;5:553-63.
42. Herbert TP, Tee AR Proud CG. The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites. J Biol Chem 2002;277:11591-96.
43. Nomura M, He Z, Koyama I, Ma WY, Miyamoto K, Dong Z. Involvement of the Akt/mTOR pathway on EGF-induced cell transformation. Mol Carcinog 2003;38: 25-32.
44. Takeuchi H, Kondo Y, Fujiwara K, et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 2005;65: 3336-46.
45. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 2005;102:802-7.